See related Regpara film-coated tab information 
 
Manufacturer Kyowa Hakko Kirin 
Distributor Hong Kong: LF Asia/Macau: Four Star 
Contents Cinacalcet HCl
Indications Secondary hyperparathyroidism in patients undergoing maintenance dialysis.
Dosage Initially 25 mg once daily, may be adjusted to 25-75 mg once daily. Increase dose by 25 mg at 3-wk intervals up to 100 mg once daily if required or if there is no improvement on the parathyroid hormone (PTH).
Administration May be taken with or without food (May be taken w/ meals for better absorption.).
Special Precautions Determine serum Ca & PTH level prior to & periodically during therapy. Decrease dose as needed if serum Ca level is ≤8.4 mg/dL or w/draw if ≤7.5 mg/dL. Hypocalcemia, seizure, hepatic dysfunction. Pregnancy & lactation. Low birthwt infant, childn.
Adverse Drug Reactions GI disturbances, hypocalcemia, prolonged QT interval, decreased level or temporary loss of consciousness.
View ADR Monitoring Form
Drug Interactions Azole antifungals, macrolides, amiodarone HCl, grapefruit juice, TCAs, butyrophenone antipsychotics, flecainide, vinblastine, calcitonin, bisphosphonates, corticosteroids, digitoxin, diazepam.
View more drug interactions with Regpara
Pregnancy Category (US FDA)      
     
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. 
ATC Classification H05BX01 - cinacalcet ; Belongs to the class of other anti-parathyroid agents. Used in the management of calcium homeostasis. 

Presentation/Packing
Form Packing Photo
Regpara film-coated tablet  Regpara 25 mg x 100's
 
Manufacturer: Kyowa Hakko Kirin
 
Distributor: Hong Kong: LF Asia
Macau: Four Star